FDA Announces Recall of Lidocaine HCL

Hospira, Inc. is recalling one lot of Lidocaine HCI Injection, USP, 2%, 20 mg per mL, 5 mL single-Dose Vial, Preservative-Free (NDC 0409-2066-05; Lot 25-550-DD, Expiry 1JAN2015) to the user level due to a confirmed customer report of discolored product with visible particles in the solution as well as particulate embedded in the molded glass container. Hospira has identified the particulate as iron oxide.

Check the lot numbers of your inventory to see if you have any affected product and contact Hospira or your dealer for instructions on exchanging the affected product.


Please note, comments must be approved before they are published